Migraine - FOI Response Register

1. Please provide the number of migraine patients treated in the last 4 months with:

Where we have provided <5 answers this is because NHS Shetland considers that providing more specific information carries a high risk of identifying (or disclosing information about) individual patients. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

2. How many patients have you treated in the last 4 months for acute migraine with:

•           Rimegepant (Vydura)

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.

In keeping with its duty to provide advice and assistance, NHS Shetland estimates that around six patients use “abortive doses” for acute migraine.

3. Are you required to complete Blueteq for the following product classes:

N/A in Scotland

•           Botulinum Toxin (Botox, Dysport, Xeomin)

•           Monoclonal antibodies (e.g. Fremanezumab, Erenumab, Galcanezumab, Eptinezumab)

•           Gepants (e.g. Rimegepant, Atogepant)